Aurobindo Pharma’s arm gets warning letter from USFDA for Unit-III

16 Aug 2024 Evaluate

Aurobindo Pharma’s wholly owned subsidiary -- Eugia Pharma Specialities’ Unit-III, a Formulation manufacturing facility has received a Warning Letter from United States Food and Drug Administration (USFDA). There is no impact on the existing supplies to the US markets. 

In May 2024, USFDA had determined the inspection classification status to Aurobindo Pharma’s wholly owned subsidiary -- Eugia Pharma Specialities’ unit III, formulation manufacturing facility as ‘Official Action Indicated (OAI)’.

Aurobindo Pharma is engaged in manufacturing pharmaceutical products. It offers active pharmaceutical ingredients, intermediates and generic formulations like astemizole, domeperidone and omeprazole; anti-infective, oral and sterile antibiotics, pain management and osteoporosis segments.

Aurobindo Pharma Share Price

1240.70 -14.70 (-1.17%)
20-Dec-2024 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1808.50
Dr. Reddys Lab 1342.45
Cipla 1472.45
Lupin 2147.55
Zydus Lifesciences 973.90
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.